Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research

Clarissa Berardo, Laura Giuseppina Di Pasqua, Marta Cagna, Plinio Richelmi, Mariapia Vairetti, Andrea Ferrigno, Clarissa Berardo, Laura Giuseppina Di Pasqua, Marta Cagna, Plinio Richelmi, Mariapia Vairetti, Andrea Ferrigno

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a continuum of liver abnormalities often starting as simple steatosis and to potentially progress into nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma. Because of its increasing prevalence, NAFLD is becoming a major public health concern, in parallel with a worldwide increase in the recurrence rate of diabetes and metabolic syndrome. It has been estimated that NASH cirrhosis may surpass viral hepatitis C and become the leading indication for liver transplantation in the next decades. The broadening of the knowledge about NASH pathogenesis and progression is of pivotal importance for the discovery of new targeted and more effective therapies; aim of this review is to offer a comprehensive and updated overview on NAFLD and NASH pathogenesis, the most recommended treatments, drugs under development and new drug targets. The most relevant in vitro and in vivo models of NAFLD and NASH will be also reviewed, as well as the main molecular pathways involved in NAFLD and NASH development.

Keywords: hepatocellular carcinoma; metabolic syndrome; non-alcoholic fatty liver disease; steatohepatitis; steatosis.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Non-alcoholic steatohepatitis (NASH) pathogenesis. Free fatty acids have a key role in the pathogenesis of NASH. Free fatty acids primarily originate from lipolysis of triglycerides in adipose tissue; insulin resistance may contribute to NASH through a lipolysis dysregulation. The other major contributor to the free fatty acid liver accumulation is de novo lipogenesis (DNL), resulting from hepatocyte-mediated conversion of fructose to fatty acids. Fatty acids, in hepatocytes, are directed toward mitochondrial beta-oxidation or re-esterification to form triglycerides. Triglycerides can be exported into the blood as VLDL or stored in lipid droplets. When the beta-oxidation or triglyceride conversion of fatty acids is overwhelmed, lipotoxicity occurs, leading to ER stress, oxidative stress and inflammasome activation. These processes are responsible for NASH development, resulting in hepatocellular injury, inflammation and fibrosis.
Figure 2
Figure 2
Mechanism of NAFLD pathogenesis in in vivo models. FA accumulation has a key role in NAFLD and NASH development. In ob/ob, Db/Db and Zucker models, a leptin-related increase in appetite results in insulin resistance and FA accumulation. HFD and fructose-rich diets induce insulin resistance and, secondarily, liposysis; HFD also causes a higher FA intake. In SREBP-c1 genetic model, FA increase is caused by a higher level of lipogenesis. MCD diet inhibits VLDL synthesis and export, as well as a GSH deficiency, leading to oxidative stress. ↑ indicates an increase. HFD, high-fat diet; SREBP-1c, sterol regulatory element-binding protein 1c; MCD, methionine and choline deficient; VLDL, very low-density lipoprotein.

References

    1. Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018;15:11–20. doi: 10.1038/nrgastro.2017.109.
    1. Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism. 2016;65:1038–1048. doi: 10.1016/j.metabol.2015.12.012.
    1. Schaffner F., Thaler H. Nonalcoholic fatty liver disease. Prog. Liver Dis. 1986;8:283–298.
    1. Bertot L.C., Adams L.A. The natural course of non-alcoholic fatty liver disease. Int. J. Mol. Sci. 2016;17:774. doi: 10.3390/ijms17050774.
    1. Charlton M. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr. Opin. Organ Transplant. 2013;18:251–258. doi: 10.1097/MOT.0b013e3283615d30.
    1. Allen L.N., Feigl A.B. What’s in a name? A call to reframe non-communicable diseases. Lancet Glob. Health. 2017;5:e129–e130. doi: 10.1016/S2214-109X(17)30001-3.
    1. Fouad Y., Waked I., Bollipo S., Gomaa A., Ajlouni Y., Attia D. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int. 2020;40:1254–1261. doi: 10.1111/liv.14478.
    1. Eslam M., Newsome P.N., Sarin S.K., Anstee Q.M., Targher G., Romero-Gomez M., Zelber-Sagi S., Wai-Sun Wong V., Dufour J.F., Schattenberg J.M., et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020;73:202–209. doi: 10.1016/j.jhep.2020.03.039.
    1. Polyzos S.A., Kang E.S., Tsochatzis E.A., Kechagias S., Ekstedt M., Xanthakos S., Lonardo A., Mantovani A., Tilg H., Côté I., et al. Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism. 2020;113:154413. doi: 10.1016/j.metabol.2020.154413.
    1. Targher G. Concordance between MAFLD and NAFLD diagnostic criteria in ‘real-world’ data. Liver Int. 2020;40:2879–2880. doi: 10.1111/liv.14623.
    1. Huang J., Kumar R., Zhu Y., Lin S. Authors’ response to ‘Concordance of MAFLD and NAFLD diagnostic criteria in “real-world” data’. Liver Int. 2020;40:2880–2881. doi: 10.1111/liv.14656.
    1. Godoy-Matos A.F., Silva Júnior W.S., Valerio C.M. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol. Metab. Syndr. 2020;12:60. doi: 10.1186/s13098-020-00570-y.
    1. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet. 2005;365:1415–1428. doi: 10.1016/S0140-6736(05)66378-7.
    1. Saklayen M.G. The Global Epidemic of the Metabolic Syndrome. Curr. Hypertens. Rep. 2018;20:12. doi: 10.1007/s11906-018-0812-z.
    1. Jinjuvadia R., Antaki F., Lohia P., Liangpunsakul S. The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States Population. J. Clin. Gastroenterol. 2017;51:160–166. doi: 10.1097/MCG.0000000000000666.
    1. Kim D., Chung G.E., Kwak M.S., Seo H.B., Kang J.H., Kim W., Kim Y.J., Yoon J.H., Lee H.S., Kim C.Y. Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 2016;14:132–138.e4. doi: 10.1016/j.cgh.2015.07.024.
    1. Dai W., Ye L., Liu A., Wen S.W., Deng J., Wu X., Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. Medicine. 2017;96 doi: 10.1097/MD.0000000000008179.
    1. Younossi Z.M., Golabi P., de Avila L., Paik J.M., Srishord M., Fukui N., Qiu Y., Burns L., Afendy A., Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 2019;71:793–801. doi: 10.1016/j.jhep.2019.06.021.
    1. Younossi Z.M., Marchesini G., Pinto-Cortez H., Petta S. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Transplantation. 2019;103:22–27. doi: 10.1097/TP.0000000000002484.
    1. Lonardo A., Suzuki A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. J. Clin. Med. 2020;9:1278. doi: 10.3390/jcm9051278.
    1. Arun J., Clements R.H., Lazenby A.J., Leeth R.R., Abrams G.A. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes. Surg. 2006;16:1351–1358. doi: 10.1381/096089206778663715.
    1. Iqbal U., Perumpail B.J., Akhtar D., Kim D., Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines. 2019;6:41. doi: 10.3390/medicines6010041.
    1. Smith S.K., Perito E.R. Nonalcoholic Liver Disease in Children and Adolescents. Clin. Liver Dis. 2018;22:723–733. doi: 10.1016/j.cld.2018.07.001.
    1. Otgonsuren M., Stepanova M., Gerber L., Younossi Z.M. Anthropometric and clinical factors associated with mortality in Subjects with nonalcoholic fatty liver disease. Dig. Dis. Sci. 2013;58:1132–1140. doi: 10.1007/s10620-012-2446-3.
    1. Stepanova M., Rafiq N., Makhlouf H., Agrawal R., Kaur I., Younoszai Z., McCullough A., Goodman Z., Younossi Z.M. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD) Dig. Dis. Sci. 2013;58:3017–3023. doi: 10.1007/s10620-013-2743-5.
    1. Younossi Z.M., Stepanova M., Rafiq N., Makhlouf H., Younoszai Z., Agrawal R., Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–1882. doi: 10.1002/hep.24268.
    1. Ekstedt M., Franzén L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873. doi: 10.1002/hep.21327.
    1. Golabi P., Otgonsuren M., De Avila L., Sayiner M., Rafiq N., Younossi Z.M. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD) Medicine. 2018;97 doi: 10.1097/MD.0000000000010214.
    1. Younossi Z.M., Otgonsuren M., Venkatesan C., Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism. 2013;62:352–360. doi: 10.1016/j.metabol.2012.08.005.
    1. Stepanova M., Rafiq N., Younossi Z.M. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: A population-based study. Gut. 2010;59:1410–1415. doi: 10.1136/gut.2010.213553.
    1. Elsheikh E., Younoszai Z., Otgonsuren M., Hunt S., Raybuck B., Younossi Z.M. Markers of endothelial dysfunction in patients with non-alcoholic fatty liver disease and coronary artery disease. J. Gastroenterol. Hepatol. 2014;29:1528–1534. doi: 10.1111/jgh.12549.
    1. Mittal S., Sada Y.H., El-Serag H.B., Kanwal F., Duan Z., Temple S., May S.B., Kramer J.R., Richardson P.A., Davila J.A. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin. Gastroenterol. Hepatol. 2015;13:594–601.e1. doi: 10.1016/j.cgh.2014.08.013.
    1. Lonardo A., Ballestri S. Perspectives of nonalcoholic fatty liver disease research: A personal point of view. Explor. Med. 2020;1:85–107. doi: 10.37349/emed.2020.00007.
    1. Alkhouri N., Feldstein A.E. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism. 2016;65:1087–1095. doi: 10.1016/j.metabol.2016.01.013.
    1. Dyson J.K., Anstee Q.M., McPherson S. Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5:211–218. doi: 10.1136/flgastro-2013-100403.
    1. Ferraioli G., Monteiro L.B.S. Ultrasound-based techniques for the diagnosis of liver steatosis. World J. Gastroenterol. 2019;25:6053–6062. doi: 10.3748/wjg.v25.i40.6053.
    1. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64:1388–1402. doi: 10.1016/j.jhep.2015.11.004.
    1. Feldstein A.E., Wieckowska A., Lopez A.R., Liu Y.C., Zein N.N., McCullough A.J. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology. 2009;50:1072–1078. doi: 10.1002/hep.23050.
    1. Wieckowska A., Zein N.N., Yerian L.M., Lopez A.R., McCullough A.J., Feldstein A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27–33. doi: 10.1002/hep.21223.
    1. Croce A.C.A.C., Ferrigno A., Di Pasqua L.G.L.G., Berardo C., Piccolini V.M.V.M., Bertone V., Bottiroli G., Vairetti M. Autofluorescence discrimination of metabolic fingerprint in nutritional and genetic fatty liver models. J. Photochem. Photobiol. B Biol. 2016;164:13–20. doi: 10.1016/j.jphotobiol.2016.09.015.
    1. Croce A.C.A.C., Ferrigno A., Bertone V., Piccolini V.M.V.M., Berardo C., Di Pasqua L.G.L.G., Rizzo V., Bottiroli G., Vairetti M. Fatty liver oxidative events monitored by autofluorescence optical diagnosis: Comparison between subnormothermic machine perfusion and conventional cold storage preservation. Hepatol. Res. 2016;47:668–682. doi: 10.1111/hepr.12779.
    1. Ferrigno A., Di Pasqua L., Berardo C., Siciliano V., Rizzo V., Mannucci B., Richelmi P., Croce A., Vairetti M. Liver Graft Susceptibility during Static Cold Storage and Dynamic Machine Perfusion: DCD versus Fatty Livers. Int. J. Mol. Sci. 2017;19:109. doi: 10.3390/ijms19010109.
    1. Ferrigno A., Di Pasqua L.G., Berardo C., Richelmi P., Vairetti M. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury. World J. Gastroenterol. 2015;21:5131–5137. doi: 10.3748/wjg.v21.i17.5131.
    1. Dogru T., Genc H., Tapan S., Ercin C.N., Ors F., Aslan F., Kara M., Sertoglu E., Bagci S., Kurt I., et al. Elevated asymmetric dimethylarginine in plasma: An early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Diabetes Res. Clin. Pract. 2012;96:47–52. doi: 10.1016/j.diabres.2011.11.022.
    1. Richir M.C., Bouwman R.H., Teerlink T., Siroen M.P.C., de Vries T.P.G.M., van Leeuwen P.A.M. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. JPEN J. Parenter. Enter. Nutr. 2009;32 doi: 10.1177/0148607108321702.
    1. Boga S., Alkim H., Koksal A.R., Bayram M., Ozguven M.B.Y., Ergun M., Neijmann S.T., Ozgon G., Alkim C. Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation with Insulin Resistance, Inflammation, and Liver Histology. J. Investig. Med. 2015;63:871–877. doi: 10.1097/JIM.0000000000000230.
    1. Di Pasqua L.G., Berardo C., Rizzo V., Richelmi P., Croce A.C., Vairetti M., Ferrigno A. MCD diet-induced steatohepatitis is associated with alterations in asymmetric dimethylarginine (ADMA) and its transporters. Mol. Cell. Biochem. 2016;419:147–155. doi: 10.1007/s11010-016-2758-2.
    1. Hernández A., Arab J.P., Reyes D., Lapitz A., Moshage H., Bañales J.M., Arrese M. Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy. Cells. 2020;9:817. doi: 10.3390/cells9040817.
    1. Povero D., Eguchi A., Li H., Johnson C.D., Papouchado B.G., Wree A., Messer K., Feldstein A.E. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS ONE. 2014;9:e113651. doi: 10.1371/journal.pone.0113651.
    1. Kornek M., Lynch M., Mehta S.H., Lai M., Exley M., Afdhal N.H., Schuppan D. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology. 2012;143:448–458. doi: 10.1053/j.gastro.2012.04.031.
    1. Verdam F.J., Dallinga J.W., Driessen A., de Jonge C., Moonen E.J.C., van Berkel J.B.N., Luijk J., Bouvy N.D., Buurman W.A., Rensen S.S., et al. Non-alcoholic steatohepatitis: A non-invasive diagnosis by analysis of exhaled breath. J. Hepatol. 2013;58:543–548. doi: 10.1016/j.jhep.2012.10.030.
    1. Peverill W., Powell L.W., Skoien R. Evolving concepts in the pathogenesis of NASH: Beyond steatosis and inflammation. Int. J. Mol. Sci. 2014;15:8591–8638. doi: 10.3390/ijms15058591.
    1. Day C.P., Saksena S. Non-alcoholic steatohepatitis: Definitions and pathogenesis. J. Gastroenterol. Hepatol. 2002;17:S377–S384. doi: 10.1046/j.1440-1746.17.s3.31.x.
    1. Pan M., Cederbaum A.I., Zhang Y.-L., Ginsberg H.N., Williams K.J., Fisher E.A. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J. Clin. Investig. 2004;113:1277–1287. doi: 10.1172/JCI19197.
    1. Feldstein A., Gores G.J. Steatohepatitis and apoptosis: Therapeutic implications. Am. J. Gastroenterol. 2004;99:1718–1719. doi: 10.1111/j.1572-0241.2004.40573.x.
    1. Hebbard L., George J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2011;8:35–44. doi: 10.1038/nrgastro.2010.191.
    1. Guilherme A., Virbasius J.V., Puri V., Czech M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008;9:367–377. doi: 10.1038/nrm2391.
    1. Cusi K. Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis. Clin. Liver Dis. 2009;13:545–563. doi: 10.1016/j.cld.2009.07.009.
    1. Yilmaz Y. Review article: Is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment. Pharmacol. Ther. 2012;36:815–823.
    1. Satapathy S.K., Kuwajima V., Nadelson J., Atiq O., Sanyal A.J. Drug-induced fatty liver disease: An overview of pathogenesis and management. Ann. Hepatol. 2015;14:789–806. doi: 10.5604/16652681.1171749.
    1. Marino L., Jornayvaz F.R. Endocrine causes of nonalcoholic fatty liver disease. World J. Gastroenterol. 2015;21:11053–11076. doi: 10.3748/wjg.v21.i39.11053.
    1. Adinolfi L.E., Rinaldi L., Guerrera B., Restivo L., Marrone A., Giordano M., Zampino R. NAFLD and NASH in HCV infection: Prevalence and significance in hepatic and extrahepatic manifestations. Int. J. Mol. Sci. 2016;17:803. doi: 10.3390/ijms17060803.
    1. Esler W.P., Bence K.K. Metabolic Targets in Nonalcoholic Fatty Liver Disease. CMGH. 2019;8:247–267. doi: 10.1016/j.jcmgh.2019.04.007.
    1. Hamilton J.A., Johnson R.A., Corkey B., Kamp F. Fatty acid transport: The diffusion mechanism in model and biological membranes. J. Mol. Neurosci. 2001;16:99–108. doi: 10.1385/JMN:16:2-3:99.
    1. Schwenk R.W., Holloway G.P., Luiken J.J.F.P., Bonen A., Glatz J.F.C. Fatty acid transport across the cell membrane: Regulation by fatty acid transporters. Prostaglandins Leukot. Essent. Fat. Acids. 2010;82:149–154. doi: 10.1016/j.plefa.2010.02.029.
    1. Hajri T., Abumrad N.A. Fatty Acid Transport Across Membranes: Relevance to Nutrition and Metabolic Pathology. Annu. Rev. Nutr. 2002;22:383–415. doi: 10.1146/annurev.nutr.22.020402.130846.
    1. Koo S.H. Nonalcoholic fatty liver disease: Molecular mechanisms for the hepatic steatosis. Clin. Mol. Hepatol. 2013;19:210–215. doi: 10.3350/cmh.2013.19.3.210.
    1. Ipsen D.H., Lykkesfeldt J., Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell. Mol. Life Sci. 2018;75:3313–3327. doi: 10.1007/s00018-018-2860-6.
    1. Wilson C.G., Tran J.L., Erion D.M., Vera N.B., Febbraio M., Weiss E.J. Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice. Endocrinology. 2016;157:570–585. doi: 10.1210/en.2015-1866.
    1. Mukai T., Egawa M., Takeuchi T., Yamashita H., Kusudo T. Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease. FEBS Open Bio. 2017;7:1009–1016. doi: 10.1002/2211-5463.12240.
    1. Solinas G., Borén J., Dulloo A.G. De novo lipogenesis in metabolic homeostasis: More friend than foe? Mol. Metab. 2015;4:367–377. doi: 10.1016/j.molmet.2015.03.004.
    1. Begriche K., Massart J., Robin M.A., Bonnet F., Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58:1497–1507. doi: 10.1002/hep.26226.
    1. Imajo K., Yoneda M., Kessoku T., Ogawa Y., Maeda S., Sumida Y., Hyogo H., Eguchi Y., Wada K., Nakajima A. Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int. J. Mol. Sci. 2013;14:21833–21857. doi: 10.3390/ijms141121833.
    1. Lambert J.E., Ramos-Roman M.A., Browning J.D., Parks E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726–735. doi: 10.1053/j.gastro.2013.11.049.
    1. Qu Q., Zeng F., Liu X., Wang Q.J., Deng F. Fatty acid oxidation and carnitine palmitoyltransferase I: Emerging therapeutic targets in cancer. Cell Death Dis. 2016;7:e2226. doi: 10.1038/cddis.2016.132.
    1. Houten S.M., Wanders R.J.A. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J. Inherit. Metab. Dis. 2010;33:469–477. doi: 10.1007/s10545-010-9061-2.
    1. Yoon M. The role of PPARα in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARα actions. Pharmacol. Res. 2009;60:151–159. doi: 10.1016/j.phrs.2009.02.004.
    1. Foster D.W. Malonyl-CoA: The regulator of fatty acid synthesis and oxidation. J. Clin. Investig. 2012;122:1958–1959. doi: 10.1172/JCI63967.
    1. Zhang X., Li S., Zhou Y., Su W., Ruan X., Wang B., Zheng F., Warner M., Gustafsson J.Å., Guan Y. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proc. Natl. Acad. Sci. USA. 2017;114:3181–3185. doi: 10.1073/pnas.1700172114.
    1. Rao M.S., Reddy J.K. Peroxisomal β-oxidation and steatohepatitis. Semin. Liver Dis. 2001;21:43–55. doi: 10.1055/s-2001-12928.
    1. Perla F., Prelati M., Lavorato M., Visicchio D., Anania C. The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. Children. 2017;4:46. doi: 10.3390/children4060046.
    1. Shelness G.S., Sellers J.A. Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol. 2001;12:151–157. doi: 10.1097/00041433-200104000-00008.
    1. Schonfeld G., Patterson B.W., Yablonskiy D.A., Tanoli T.S.K., Averna M., Elias N., Yue P., Ackerman J. Fatty liver in familial hypobetalipoproteinemia: Triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J. Lipid Res. 2003;44:470–478. doi: 10.1194/jlr.M200342-JLR200.
    1. Fabbrini E., Mohammed B.S., Magkos F., Korenblat K.M., Patterson B.W., Klein S. Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women with Nonalcoholic Fatty Liver Disease. Gastroenterology. 2008;134:424–431. doi: 10.1053/j.gastro.2007.11.038.
    1. Horton J.D., Shimano H., Hamilton R.L., Brown M.S., Goldstein J.L. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Investig. 1999;103:1067–1076. doi: 10.1172/JCI6246.
    1. Laplante M., Sabatini D.M. mTOR signaling at a glance. J. Cell Sci. 2009;122:3589–3594. doi: 10.1242/jcs.051011.
    1. Bakan I., Laplante M. Connecting mTORC1 signaling to SREBP-1 activation. Curr. Opin. Lipidol. 2012;23:226–234. doi: 10.1097/MOL.0b013e328352dd03.
    1. Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., Griffiths J.R., Chung Y.L., Schulze A. SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth. Cell Metab. 2008;8:224–236. doi: 10.1016/j.cmet.2008.07.007.
    1. Düvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell. 2010;39:171–183. doi: 10.1016/j.molcel.2010.06.022.
    1. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 2002;109:1125–1131. doi: 10.1172/JCI0215593.
    1. Jump D.B., Tripathy S., Depner C.M. Fatty Acid–Regulated Transcription Factors in the Liver. Annu. Rev. Nutr. 2013;33:249–269. doi: 10.1146/annurev-nutr-071812-161139.
    1. Zhou Y., Yu S., Cai C., Zhong L., Yu H., Shen W. LXRα participates in the mTOR/S6K1/SREBP-1c signaling pathway during sodium palmitate-induced lipogenesis in HepG2 cells. Nutr. Metab. 2018;15:1–9. doi: 10.1186/s12986-018-0268-9.
    1. Sangüesa G., Roglans N., Baena M., Velázquez A.M., Laguna J.C., Alegret M. mTOR is a key protein involved in the metabolic effects of simple sugars. Int. J. Mol. Sci. 2019;20:1117. doi: 10.3390/ijms20051117.
    1. Caron A., Richard D., Laplante M. The Roles of mTOR Complexes in Lipid Metabolism. Annu. Rev. Nutr. 2015;35:321–348. doi: 10.1146/annurev-nutr-071714-034355.
    1. Han J., Li E., Chen L., Zhang Y., Wei F., Liu J., Deng H., Wang Y. The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1. Nature. 2015;524:243–246. doi: 10.1038/nature14557.
    1. Peterson T.R., Sengupta S.S., Harris T.E., Carmack A.E., Kang S.A., Balderas E., Guertin D.A., Madden K.L., Carpenter A.E., Finck B.N., et al. MTOR complex 1 regulates lipin 1 localization to control the srebp pathway. Cell. 2011;146:408–420. doi: 10.1016/j.cell.2011.06.034.
    1. Lamichane S., Dahal Lamichane B., Kwon S.-M. Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis. Int. J. Mol. Sci. 2018;19:949. doi: 10.3390/ijms19040949.
    1. Pyper S.R., Viswakarma N., Yu S., Reddy J.K. PPARalpha: Energy combustion, hypolipidemia, inflammation and cancer. Nucl. Recept. Signal. 2010;8:nrs-08002. doi: 10.1621/nrs.08002.
    1. Wang Y., Nakajima T., Gonzalez F.J., Tanaka N. PPARs as metabolic regulators in the liver: Lessons from liver-specific PPAR-null mice. Int. J. Mol. Sci. 2020;21:2061. doi: 10.3390/ijms21062061.
    1. Yu G.S., Lu Y.C., Gulick T. Co-regulation of tissue-specific alternative human carnitine palmitoyltransferase Iβ gene promoters by fatty acid enzyme substrate. J. Biol. Chem. 1998;273:32901–32909. doi: 10.1074/jbc.273.49.32901.
    1. Maeda T., Wakasawa T., Funabashi M., Fukushi A., Fujita M., Motojima K., Tamai I. Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha. Biol. Pharm. Bull. 2008;31:1230–1236. doi: 10.1248/bpb.31.1230.
    1. Rakhshandehroo M., Knoch B., Müller M., Kersten S. Peroxisome Proliferator-Activated Receptor Alpha Target Genes. PPAR Res. 2010;2010:612089. doi: 10.1155/2010/612089.
    1. Kersten S. Integrated physiology and systems biology of PPARα. Mol. Metab. 2014;3:354–371. doi: 10.1016/j.molmet.2014.02.002.
    1. Liss K.H.H., Finck B.N. PPARs and nonalcoholic fatty liver disease. Biochimie. 2017;136:65–74. doi: 10.1016/j.biochi.2016.11.009.
    1. Pawlak M., Lefebvre P., Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 2015;62:720–733. doi: 10.1016/j.jhep.2014.10.039.
    1. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R.A., Briggs M., Deeb S., Staels B., Auwerx J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336–5348. doi: 10.1002/j.1460-2075.1996.tb00918.x.
    1. Kersten S. Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res. 2008;2008:173780. doi: 10.1155/2008/132960.
    1. Sahebkar A., Simental-Mendía L.E., Katsiki N., Reiner Ž., Banach M., Pirro M., Atkin S.L. Effect of fenofibrate on plasma apolipoprotein C-III levels: A systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2018;8 doi: 10.1136/bmjopen-2018-021508.
    1. Grabacka M., Pierzchalska M., Dean M., Reiss K. Regulation of ketone body metabolism and the role of PPARα. Int. J. Mol. Sci. 2016;17:2093. doi: 10.3390/ijms17122093.
    1. Jiao M., Ren F., Zhou L., Zhang X., Zhang L., Wen T., Wei L., Wang X., Shi H., Bai L., et al. Peroxisome proliferator-activated receptor α activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway. Cell Death Dis. 2014;5 doi: 10.1038/cddis.2014.361.
    1. Mansouri R.M., Baugé E., Staels B., Gervois P. Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-α control of the acute-phase response. Endocrinology. 2008;149:3215–3223. doi: 10.1210/en.2007-1339.
    1. Fernández-Alvarez A., Soledad Alvarez M., Gonzalez R., Cucarella C., Muntané J., Casado M. Human SREBP1c expression in liver is directly regulated by Peroxisome Proliferator-activated Receptor α (PPARα) J. Biol. Chem. 2011;286:21466–21477. doi: 10.1074/jbc.M110.209973.
    1. Knight B.L., Hebbach A., Hauton D., Brown A.M., Wiggins D., Patel D.D., Gibbons G.F. A role for PPARα in the control of SREBP activity and lipid synthesis in the liver. Biochem. J. 2005;389:413–421. doi: 10.1042/BJ20041896.
    1. Tang C., Cho H.P., Nakamura M.T., Clarke S.D. Regulation of human Δ-6 desaturase gene transcription: Identification of a functional direct repeat-1 element. J. Lipid Res. 2003;44:686–695. doi: 10.1194/jlr.M200195-JLR200.
    1. Xu P., Zhai Y., Wang J. The role of PPAR and its cross-talk with CAR and LXR in obesity and atherosclerosis. Int. J. Mol. Sci. 2018;19:1260. doi: 10.3390/ijms19041260.
    1. Lazennec G., Canaple L., Saugy D., Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol. Endocrinol. 2000;14:1962–1975. doi: 10.1210/mend.14.12.0575.
    1. Sengupta S., Peterson T.R., Laplante M., Oh S., Sabatini D.M. MTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature. 2010;468:1100–1106. doi: 10.1038/nature09584.
    1. Bockaert J., Marin P. mTOR in brain physiology and pathologies. Physiol. Rev. 2015;95:1157–1187. doi: 10.1152/physrev.00038.2014.
    1. Ferraguti F., Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res. 2006 doi: 10.1007/s00441-006-0266-5.
    1. Yin S., Niswender C.M. Progress toward advanced understanding of metabotropic glutamate receptors: Structure, signaling and therapeutic indications. Cell. Signal. 2014;26:2284–2297. doi: 10.1016/j.cellsig.2014.04.022.
    1. Willard S.S., Koochekpour S. Glutamate, glutamate receptors, and downstream signaling pathways. Int. J. Biol. Sci. 2013;9:948–959. doi: 10.7150/ijbs.6426.
    1. Hou L., Klann E. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 2004;24:6352–6361. doi: 10.1523/JNEUROSCI.0995-04.2004.
    1. Ronesi J.A., Huber K.M. Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J. Neurosci. 2008;28:543–547. doi: 10.1523/JNEUROSCI.5019-07.2008.
    1. Abd-Elrahman K.S., Ferguson S.S.G. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington’s pathology in zQ175 mice. Mol. Brain. 2019;12:1–9. doi: 10.1186/s13041-019-0456-1.
    1. Bradbury M.J., Campbell U., Giracello D., Chapman D., King C., Tehrani L., Cosford N.D.P., Anderson J., Varney M.A., Strack A.M. Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. J. Pharmacol. Exp. Ther. 2005;313:395–402. doi: 10.1124/jpet.104.076406.
    1. Choi W.M., Kim H.H., Kim M.H., Cinar R., Yi H.S., Eun H.S., Kim S.H., Choi Y.J., Lee Y.S., Kim S.Y., et al. Glutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis. Cell Metab. 2019;30:877–889.e7. doi: 10.1016/j.cmet.2019.08.001.
    1. Khalil R.M., Khedr N.F. Curcumin protects against monosodium glutamate neurotoxicity and decreasing NMDA2B and mGluR5 expression in rat hippocampus. NeuroSignals. 2016;24:81–87. doi: 10.1159/000442614.
    1. Collison K.S., Maqbool Z., Saleh S.M., Inglis A., Makhoul N.J., Bakheet R., Al-Johi M., Al-Rabiah R., Zaidi M.Z., Al-Mohanna F.A. Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. J. Lipid Res. 2009;50:1521–1537. doi: 10.1194/jlr.M800418-JLR200.
    1. Nakanishi Y., Tsuneyama K., Fujimoto M., Salunga T.L., Nomoto K., An J.L., Takano Y., Iizuka S., Nagata M., Suzuki W., et al. Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia. J. Autoimmun. 2008;30:42–50. doi: 10.1016/j.jaut.2007.11.016.
    1. Ferrigno A., Berardo C., Di Pasqua L., Cagna M., Siciliano V., Richelmi P., Vairetti M. The selective blockade of metabotropic glutamate receptor-5 attenuates fat accumulation in an in vitro model of benign steatosis. Eur. J. Histochem. 2020;64:3175. doi: 10.4081/ejh.2020.3175.
    1. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., Friedman S.L., Diago M., Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367–378.e5. doi: 10.1053/j.gastro.2015.04.005.
    1. Munteanu M.A., Nagy G.A., Mircea P.A. Current Management of NAFLD. Clujul Med. 2016;89:19–23. doi: 10.15386/cjmed-539.
    1. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Investig. 2001;108:1167–1174. doi: 10.1172/JCI13505.
    1. Musso G., Gambino R., Cassader M., Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79–104. doi: 10.1002/hep.23623.
    1. Zhou Y.-Y., Zhu G.-Q., Liu T., Zheng J.-N., Cheng Z., Zou T.-T., Braddock M., Fu S.-W., Zheng M.-H. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. Sci. Rep. 2016;6:33743. doi: 10.1038/srep33743.
    1. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., Neuschwander-Tetri B.A., Lavine J.E., Tonascia J., Unalp A., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010;362:1675–1685. doi: 10.1056/NEJMoa0907929.
    1. Mahady S.E., Webster A.C., Walker S., Sanyal A., George J. The role of thiazolidinediones in non-alcoholic steatohepatitis—A systematic review and meta analysis. J. Hepatol. 2011;55:1383–1390. doi: 10.1016/j.jhep.2011.03.016.
    1. Friedman S.L., Neuschwander-Tetri B.A., Rinella M., Sanyal A.J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 2018;24:908–922. doi: 10.1038/s41591-018-0104-9.
    1. Ratziu V., Caldwell S., Neuschwander-Tetri B.A. Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues. Hepatology. 2010;52:2206–2215. doi: 10.1002/hep.24042.
    1. Baggio L.L., Drucker D.J. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157. doi: 10.1053/j.gastro.2007.03.054.
    1. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., Thøgersen H., Wilken M., Agersø H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 2000;43:1664–1669. doi: 10.1021/jm9909645.
    1. Astrup A., Rössner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., Madsen J., Rasmussen M.F., Lean M.E. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616. doi: 10.1016/S0140-6736(09)61375-1.
    1. Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., Hazlehurst J.M., Guo K., Abouda G., Aldersley M.A., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–690. doi: 10.1016/S0140-6736(15)00803-X.
    1. Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V., Sanyal A.J., Sejling A.-S., Harrison S.A. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2028395.
    1. Caldwell S. NASH Therapy: Omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin. Mol. Hepatol. 2017;23:103–108. doi: 10.3350/cmh.2017.0103.
    1. Saremi A., Arora R. Vitamin E and cardiovascular disease. Am. J. Ther. 2010;17:e56–e65. doi: 10.1097/MJT.0b013e31819cdc9a.
    1. Lippman S.M., Klein E.A., Goodman P.J., Lucia M.S., Thompson I.M., Ford L.G., Parnes H.L., Minasian L.M., Gaziano J.M., Hartline J.A., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA. 2009;301:39–51. doi: 10.1001/jama.2008.864.
    1. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation. Physiol. Rev. 2009;89:147–191. doi: 10.1152/physrev.00010.2008.
    1. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., Shan B. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365. doi: 10.1126/science.284.5418.1362.
    1. Wang H., Chen J., Hollister K., Sowers L.C., Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell. 1999;3:543–553. doi: 10.1016/S1097-2765(00)80348-2.
    1. Kawamata Y., Fujii R., Hosoya M., Harada M., Yoshida H., Miwa M., Fukusumi S., Habata Y., Itoh T., Shintani Y., et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 2003;278:9435–9440. doi: 10.1074/jbc.M209706200.
    1. Hollman D.A.A., Milona A., van Erpecum K.J., van Mil S.W.C. Anti-inflammatory and metabolic actions of FXR: Insights into molecular mechanisms. Biochim. Biophys. Acta. 2012;1821:1443–1452. doi: 10.1016/j.bbalip.2012.07.004.
    1. Mudaliar S., Henry R.R., Sanyal A.J., Morrow L., Marschall H.U., Kipnes M., Adorini L., Sciacca C.I., Clopton P., Castelloe E., et al. Efficacy and safety of the farnesoid x receptor agonist Obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145 doi: 10.1053/j.gastro.2013.05.042.
    1. Neuschwander-Tetri B.A., Van Natta M.L., Tonascia J., Brunt E.M., Kleiner D.E. Trials of obeticholic acid for non-alcoholic steatohepatitis—Authors’ reply. Lancet. 2015;386:28–29. doi: 10.1016/S0140-6736(15)61200-4.
    1. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., Chalasani N., Dasarathy S., Diehl A.M., Hameed B., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965. doi: 10.1016/S0140-6736(14)61933-4.
    1. Tang J.T., Mao Y.M. Development of new drugs for the treatment of nonalcoholic steatohepatitis. J. Dig. Dis. 2020;21:3–11. doi: 10.1111/1751-2980.12830.
    1. Wong V.W.S., Wong G.L.H., Chan F.K.L. Is obeticholic acid the solution to nonalcoholic steatohepatitis? Gastroenterology. 2015;148:851–852. doi: 10.1053/j.gastro.2015.02.044.
    1. Younossi Z.M., Ratziu V., Loomba R., Rinella M., Anstee Q.M., Goodman Z., Bedossa P., Geier A., Beckebaum S., Newsome P.N., et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–2196. doi: 10.1016/S0140-6736(19)33041-7.
    1. Mullard A. FDA rejects NASH drug. Nat. Rev. Drug Discov. 2020;19:501. doi: 10.1038/d41573-020-00126-9.
    1. Bojic L., Huff M. Peroxisome proliferator-activated receptor δ: A multifaceted metabolic player. Curr. Opin. Lipidol. 2013;24:171–177. doi: 10.1097/MOL.0b013e32835cc949.
    1. Odegaard J.I., Ricardo-Gonzalez R.R., Red Eagle A., Vats D., Morel C.R., Goforth M.H., Subramanian V., Mukundan L., Ferrante A.W., Chawla A. Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance. Cell Metab. 2008;7:496–507. doi: 10.1016/j.cmet.2008.04.003.
    1. Staels B., Rubenstrunk A., Noel B., Rigou G., Delataille P., Millatt L.J., Baron M., Lucas A., Tailleux A., Hum D.W., et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941–1952. doi: 10.1002/hep.26461.
    1. Ratziu V., Harrison S.A., Francque S., Bedossa P., Lehert P., Serfaty L., Romero-Gomez M., Boursier J., Abdelmalek M., Caldwell S., et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016;150:1147–1159.e5. doi: 10.1053/j.gastro.2016.01.038.
    1. Westerouen Van Meeteren M.J., Drenth J.P.H., Tjwa E.T.T.L. Elafibranor: A potential drug for the treatment of nonalcoholic steatohepatitis (NASH) Expert Opin. Investig. Drugs. 2020;29:117–123. doi: 10.1080/13543784.2020.1668375.
    1. Kim C.W., Addy C., Kusunoki J., Anderson N.N., Deja S., Fu X., Burgess S.C., Li C., Chakravarthy M., Previs S., et al. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab. 2017;26:394–406.e6. doi: 10.1016/j.cmet.2017.07.009.
    1. Barreyro F.J., Holod S., Finocchietto P.V., Camino A.M., Aquino J.B., Avagnina A., Carreras M.C., Poderoso J.J., Gores G.J. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953–966. doi: 10.1111/liv.12570.
    1. Garcia-Tsao G., Bosch J., Kayali Z., Harrison S.A., Abdelmalek M.F., Lawitz E., Satapathy S.K., Ghabril M., Shiffman M.L., Younes Z.H., et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J. Hepatol. 2020;72:885–895. doi: 10.1016/j.jhep.2019.12.010.
    1. Loomba R., Lawitz E., Mantry P.S., Jayakumar S., Caldwell S.H., Arnold H., Diehl A.M., Djedjos C.S., Han L., Myers R.P., et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67:549–559. doi: 10.1002/hep.29514.
    1. Harrison S.A., Wong V.W.S., Okanoue T., Bzowej N., Vuppalanchi R., Younes Z., Kohli A., Sarin S., Caldwell S.H., Alkhouri N., et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J. Hepatol. 2020;73:26–39. doi: 10.1016/j.jhep.2020.02.027.
    1. Washington K., Wright K., Shyr Y., Hunter E.B., Olson S., Raiford D.S. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum. Pathol. 2000;31:822–828. doi: 10.1053/hupa.2000.8440.
    1. Reid D.T., Reyes J.L., McDonald B.A., Vo T., Reimer R.A., Eksteen B. Kupffer Cells Undergo Fundamental Changes during the Development of Experimental NASH and Are Critical in Initiating Liver Damage and Inflammation. PLoS ONE. 2016;11:e0159524. doi: 10.1371/journal.pone.0159524.
    1. Hirsova P., Ibrahim S.H., Gores G.J., Malhi H. Lipotoxic Lethal and Sublethal Stress Signaling in Hepatocytes: Relevance to NASH Pathogenesis. J. Lipid Res. 2016 doi: 10.1194/jlr.R066357.
    1. Oseini A.M., Cole B.K., Issa D., Feaver R.E., Sanyal A.J. Translating scientific discovery: The need for preclinical models of nonalcoholic steatohepatitis. Hepatol. Int. 2018;12:6–16. doi: 10.1007/s12072-017-9838-6.
    1. Chavez-Tapia N.C., Rosso N., Tiribelli C. In vitro models for the study of non-alcoholic fatty liver disease. Curr. Med. Chem. 2011;18:1079–1084. doi: 10.2174/092986711794940842.
    1. Zhu C., Xie P., Zhao F., Zhang L., An W., Zhan Y. Mechanism of the promotion of steatotic HepG2 cell apoptosis by cholesterol. Int. J. Clin. Exp. Pathol. 2014;7:6807–6813.
    1. Cui W., Chen S.L., Hu K.Q. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am. J. Transl. Res. 2010;2:95–104.
    1. Ishii M., Maeda A., Tani S., Akagawa M. Palmitate induces insulin resistance in human HepG2 hepatocytes by enhancing ubiquitination and proteasomal degradation of key insulin signaling molecules. Arch. Biochem. Biophys. 2015;566:26–35. doi: 10.1016/j.abb.2014.12.009.
    1. Gómez-Lechón M.J., Donato M.T., Martínez-Romero A., Jiménez N., Castell J.V., O’Connor J.E. A human hepatocellular in vitro model to investigate steatosis. Chem. Biol. Interact. 2007;165:106–116. doi: 10.1016/j.cbi.2006.11.004.
    1. Natarajan V., Harris E.N., Kidambi S. SECs (Sinusoidal Endothelial Cells), Liver Microenvironment, and Fibrosis. BioMed Res. Int. 2017;2017:4097205. doi: 10.1155/2017/4097205.
    1. Giraudi P.J., Barbero Becerra V.J., Marin V., Chavez-Tapia N.C., Tiribelli C., Rosso N. The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation. Exp. Mol. Pathol. 2015;98:85–92. doi: 10.1016/j.yexmp.2014.12.006.
    1. Barbero-Becerra V.J., Giraudi P.J., Chávez-Tapia N.C., Uribe M., Tiribelli C., Rosso N. The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH. Toxicol. In Vitro. 2015;29:1753–1758. doi: 10.1016/j.tiv.2015.07.010.
    1. Davidson M.D., Kukla D.A., Khetani S.R. Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development. Integr. Biol. 2017;9:662–677. doi: 10.1039/C7IB00027H.
    1. Pingitore P., Sasidharan K., Ekstrand M., Prill S., Lindén D., Romeo S. Human multilineage 3D spheroids as a model of liver steatosis and fibrosis. Int. J. Mol. Sci. 2019;20:1629. doi: 10.3390/ijms20071629.
    1. Hurrell T., Kastrinou-Lampou V., Fardellas A., Hendriks D.F.G., Nordling Å., Johansson I., Baze A., Parmentier C., Richert L., Ingelman-Sundberg M. Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis. Cells. 2020;9:964. doi: 10.3390/cells9040964.
    1. Prior N., Inacio P., Huch M. Liver organoids: From basic research to therapeutic applications. Gut. 2019;68:2228–2237. doi: 10.1136/gutjnl-2019-319256.
    1. Ouchi R., Togo S., Kimura M., Shinozawa T., Koido M., Koike H., Thompson W., Karns R.A., Mayhew C.N., McGrath P.S., et al. Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids. Cell Metab. 2019;30:374–384.e6. doi: 10.1016/j.cmet.2019.05.007.
    1. Zhong F., Zhou X., Xu J., Gao L. Rodent Models of Nonalcoholic Fatty Liver Disease. Digestion. 2020;101:522–535. doi: 10.1159/000501851.
    1. Kucera O., Cervinkova Z. Experimental models of non-alcoholic fatty liver disease in rats. World J. Gastroenterol. 2014;20:8364–8376. doi: 10.3748/wjg.v20.i26.8364.
    1. Lindström P. The physiology of obese-hyperglycemic mice [ob/ob mice] Sci. World J. 2007;7:666–685. doi: 10.1100/tsw.2007.117.
    1. Wortham M., He L., Gyamfi M., Copple B.L., Wan Y.-J.Y. The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig. Dis. Sci. 2008;53:2761–2774. doi: 10.1007/s10620-007-0193-7.
    1. Santhekadur P.K., Kumar D.P., Sanyal A.J. Preclinical models of non-alcoholic fatty liver disease. J. Hepatol. 2018;68:230–237. doi: 10.1016/j.jhep.2017.10.031.
    1. Trak-Smayra V., Paradis V., Massart J., Nasser S., Jebara V., Fromenty B. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Int. J. Exp. Pathol. 2011;92:413–421. doi: 10.1111/j.1365-2613.2011.00793.x.
    1. Fellmann L., Nascimento A.R., Tibiriça E., Bousquet P. Murine models for pharmacological studies of the metabolic syndrome. Pharmacol. Ther. 2013;137:331–340. doi: 10.1016/j.pharmthera.2012.11.004.
    1. Yang Y.Y., Tsai T.H., Huang Y.T., Lee T.Y., Chan C.C., Lee K.C., Lin H.C. Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats. Hepatology. 2012;55:1540–1550. doi: 10.1002/hep.25534.
    1. Nakayama H., Otabe S., Ueno T., Hirota N., Yuan X., Fukutani T., Hashinaga T., Wada N., Yamada K. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism. 2007;56:470–475. doi: 10.1016/j.metabol.2006.11.004.
    1. Anstee Q.M., Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006;87:1–16. doi: 10.1111/j.0959-9673.2006.00465.x.
    1. Maddineni S., Nichenametla S., Sinha R., Wilson R.P., Richie J.P. Methionine restriction affects oxidative stress and glutathione-related redox pathways in the rat. Exp. Biol. Med. 2013;238:392–399. doi: 10.1177/1535370213477988.
    1. Veteläinen R., van Vliet A., van Gulik T.M. Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model. J. Gastroenterol. Hepatol. 2007;22:1526–1533. doi: 10.1111/j.1440-1746.2006.04701.x.
    1. Ip E., Farrell G., Hall P., Robertson G., Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 2004;39:1286–1296. doi: 10.1002/hep.20170.
    1. Yu J., Ip E., Dela Peña A., Hou J.Y., Sesha J., Pera N., Hall P., Kirsch R., Leclercq I., Farrell G.C. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology. 2006;43:826–836. doi: 10.1002/hep.21108.
    1. Ikawa-Yoshida A., Matsuo S., Kato A., Ohmori Y., Higashida A., Kaneko E., Matsumoto M. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet. Int. J. Exp. Pathol. 2017;98:221–233. doi: 10.1111/iep.12240.
    1. Longato L. Non-alcoholic fatty liver disease (NAFLD): A tale of fat and sugar? Fibrogenesis Tissue Repair. 2013;6:14. doi: 10.1186/1755-1536-6-14.
    1. Spruss A., Kanuri G., Wagnerberger S., Haub S., Bischoff S.C., Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009;50:1094–1104. doi: 10.1002/hep.23122.
    1. Mamikutty N., Thent Z.C., Sapri S.R., Sahruddin N.N., Mohd Yusof M.R., Haji Suhaimi F. The establishment of metabolic syndrome model by induction of fructose drinking water in male Wistar rats. BioMed Res. Int. 2014;2014:263897. doi: 10.1155/2014/263897.
    1. Kohli R., Kirby M., Xanthakos S.A., Softic S., Feldstein A.E., Saxena V., Tang P.H., Miles L., Miles M.V., Balistreri W.F., et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology. 2010;52:934–944. doi: 10.1002/hep.23797.
    1. Matsuzawa N., Takamura T., Kurita S., Misu H., Ota T., Ando H., Yokoyama M., Honda M., Zen Y., Nakanuma Y., et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology. 2007;46:1392–1403. doi: 10.1002/hep.21874.
    1. Younossi Z.M. The epidemiology of nonalcoholic steatohepatitis. Clin. Liver Dis. 2018;11:92–94. doi: 10.1002/cld.710.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit